Newsroom | 86284 results

北京--(BUSINESS WIRE)--(美國商業資訊)-- 中國領先的生物製藥公司科興控股生物技術有限公司（Sinovac Biotech Ltd.，以下簡稱「科興」或「公司」）（納斯達克代碼：SVA）今日宣佈，美國紐約南區聯邦地區法院駁回了尚珹資本（Advantech/Prime Success，以下簡稱「尚珹資本/Prime」）的緊急禁令救濟申請，公司在此案中獲得勝訴。 紐約法院的裁決再次表明，尚珹資本/Prime與維梧資本（Vivo Capital）（合稱「異議投資者」）試圖挑戰根據樞密院裁決和安提瓜法律合法成立的科興新董事會（以下簡稱「現任科興董事會」）的控制權，並阻撓現任科興董事會宣佈的每股55.00美元特別現金股息的派發的行動再次以失敗告終。 根據紐約法院的裁決，現任科興董事會可以繼續其在安提瓜的法律行動，申請撤銷前非法董事會（以下簡稱「前冒牌董事會」）向異議投資者集團無效發行的私募配售（以下簡稱「PIPE」）股份。如此前所宣佈，如果現任科興董事會在PIPE股份訴訟中勝訴，將向科興的合法股東額外派發每股普通股11.00美元股息。 科興董事會主席李嘉強博士表示：「我們將繼...

北京--(BUSINESS WIRE)--(美国商业资讯)-- 中国领先的生物制药公司科兴控股生物技术有限公司（Sinovac Biotech Ltd.，以下简称“科兴”或“公司”）（纳斯达克代码：SVA）今日宣布，美国纽约南区联邦地区法院驳回了尚珹资本（Advantech/Prime Success，以下简称“尚珹资本/Prime”）的紧急禁令救济申请，公司在此案中获得胜诉。 纽约法院的裁决再次表明，尚珹资本/Prime与维梧资本（Vivo Capital）（合称“异议投资者”）试图挑战根据枢密院裁决和安提瓜法律合法成立的科兴新董事会（以下简称“现任科兴董事会”）的控制权，并阻挠现任科兴董事会宣布的每股55.00美元特别现金股息的派发的行动再次以失败告终。 根据纽约法院的裁决，现任科兴董事会可以继续其在安提瓜的法律行动，申请撤销前非法董事会（以下简称“前冒牌董事会”）向异议投资者集团无效发行的私募配售（以下简称“PIPE”）股份。如此前所宣布，如果现任科兴董事会在PIPE股份诉讼中胜诉，将向科兴的合法股东额外派发每股普通股11.00美元股息。 科兴董事会主席李嘉强博士表示：“我们将继...

HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the decision by the United States District Court for the Southern District of New York on Friday, June 20, 2025. Prime Success stated: “The New York court ruling confirms what we have consi...

CHICAGO--(BUSINESS WIRE)--At this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare’s MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response m...

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success’ (“Advantech/Prime”) Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the “Dis...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva’s investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions. “Our first data presentation as Verdiva Bio at the prestigious ADA meetin...

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio announces preclinical data on its mitochondrial protonophore portfolio at the American Diabetes Association’s 85th Scientific Sessions....

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the Americ...

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) today announced that the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) approved the Company’s disclosure statement for its Chapter 11 Plan of Reorganization. The disclosure statement provides creditors with detailed information on the terms of the Plan and will accompany the ballots that will be sent to the more than 600,000 claimants eligible to vote. The court has set a September 30...

WILMINGTON, Del.--(BUSINESS WIRE)--Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis...